Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Metrics to compare | ONCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCOPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −1.8x | −0.7x | |
PEG Ratio | −0.04 | −0.02 | 0.00 | |
Price/Book | 2.4x | 2.6x | 2.6x | |
Price / LTM Sales | 12.3x | 4.5x | 3.2x | |
Upside (Analyst Target) | 61.9% | 107.4% | 47.0% | |
Fair Value Upside | Unlock | 29.6% | 7.5% | Unlock |